One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
May 18, 2026 06:01 AM EDTUpdated 10:50 AM
PharmaFDA+
AstraZeneca's blood pressure pill approved, but competition could be around the corner
Elizabeth Cairns
Senior biopharma journalist
AstraZeneca CEO Pascal Soriot aims for $80B annual sales by 2030; company on track with $58.7B in 2025, despite future loss of…
The China question, FDA leadership shakeups, and other biotech news from The Readout
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that…
"We are working with the government and trying to find constructive solutions so that Americans pay less for their medicines."
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
AstraZeneca picks up FDA approval for hypertension drug
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
FDA approves AstraZeneca’s new kind of hypertension drug
FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
FDA floats possible approach to repurpose approved drugs under new uses
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
